Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 19 full-time employees. The company went IPO on 2018-06-26. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Follow-Up Questions
What is the price performance of WHWK stock?
The current price of WHWK is $2.34, it has decreased 3.04% in the last trading day.
What are the primary business themes or industries for Whitehawk Therapeutics Inc?
Whitehawk Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Whitehawk Therapeutics Inc market cap?
Whitehawk Therapeutics Inc's current market cap is $110.5M
Is Whitehawk Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Whitehawk Therapeutics Inc, including 0 strong buy, 0 buy, 5 hold, 1 sell, and 0 strong sell
